Biological Evaluation, Sterilisation and Shelf-Life Evidence under the MDR

Biological evaluation, sterilisation validation and shelf-life validation are among the most heavily evidenced areas of any EU MDR technical file. This article explains where the legal basis sits in Annex I Chapter II, how the consensus standards connect to the GSPR, and which consequences follow for Class I devices supplied sterile.

1. Key takeaways

The legal basis for a device’s biological evaluation, sterilisation validation and shelf-life validation lies in Annex I Chapter II of the MDR: the requirements on chemical, physical and biological properties, the requirements on infection and microbial contamination control, and the requirements on validation of transport and storage conditions. The evidence typically takes the form of validation reports against the ISO 10993 series, the ISO 11135 / 11137 / 11737 series and the ISO 11607 series, but these standards are consensus standards and must be tied directly to the GSPR demonstration in the technical documentation rather than presented as stand-alone compliance.

Three practical consequences deserve attention. First, the intensity of biological evaluation is driven by the nature and duration of contact with the human body, so the evaluation must start from a contact assessment rather than from a generic template. Second, Class I devices placed on the market sterile lose the self-declaration route and enter the notified body regime under Article 52. Third, shelf-life and transport validation prove the maintenance of conformity until the end of the claimed lifetime, which is a distinct body of evidence from the initial performance verification.

2. Legal basis

The table below summarises the provisions and standards cited in this article.

Because the ISO standards cited above are consensus standards rather than legislative texts, every validation report must be traceable to a specific GSPR clause in the compliance matrix, with the standard referenced as the method of demonstration.

The verification and validation part of the technical documentation under Annex II is where this evidence is presented, and each report should be indexed so that the notified body can move from the GSPR clause to the underlying method, sample size, acceptance criteria and raw result without intermediate queries. Reports that cannot be located from the matrix behave, for review purposes, like missing evidence.

3. Expert insights

Insight one: the anchor point of biological evaluation is the nature and duration of contact with the body.

Chapter II of Annex I sets requirements on chemical, physical and biological properties whose specific intensity depends on the nature of contact with the human body (surface contact, externally communicating, implantable) and on the duration of that contact. The biological evaluation in the technical documentation must therefore first record the contact nature and duration determination and only then derive the evaluation endpoints. Attaching a generic biological report without this device-specific assessment is one of the recurring findings in notified body review.

Insight two: Class I devices supplied sterile are escalated to notified body involvement.

Under the classification rules, Class I devices placed on the market in the sterile state and Class I devices with a measuring function require a notified body to be involved in the aspects of the conformity assessment relating to those characteristics, in accordance with Article 52. The practical consequence is that a Class I product loses the self-declaration path because it is made sterile, and the sterilisation validation and packaging validation fall directly within the scope of notified body assessment, which extends the timeline accordingly.

Insight three: shelf-life and transport validation are state-maintenance evidence, not initial performance evidence.

Chapter II of Annex I requires devices to remain conformant under the transport and storage conditions declared by the manufacturer. Shelf-life validation, through ageing studies, packaging integrity testing and transport simulation, demonstrates that the device still conforms at the end of its claimed lifetime. This is a different class of evidence from the initial performance verification in the technical documentation, and both classes must be present in full before a submission can be considered complete.

Insight four: reprocessing of single-use devices is governed by a dedicated common specification.

The reprocessing of single-use devices is regulated by Article 23, under which the Commission adopted Implementing Regulation (EU) 2020/1207 laying down common specifications. For reusable devices, the manufacturer must additionally provide validated reprocessing procedures covering cleaning, disinfection and sterilisation, together with evidence of the maximum number of reprocessing cycles the device can withstand while remaining safe and performing as intended.

4. Practical recommendations

1. Write the contact nature and contact duration determination at the front of the biological evaluation report, and derive the evaluation endpoints from it explicitly.
2. Perform sterilisation validation under the ISO 11135 (ethylene oxide) and ISO 11137 (radiation) systems, and retain the full validation and routine control records together.
3. Design shelf-life validation around worst-case conditions: the highest temperature and humidity, the longest transport distance and the longest storage time claimed.
4. Perform packaging validation under the ISO 11607 series, including seal strength and integrity testing, and link the results to the sterilisation method used.
5. For reusable devices, provide validation evidence for the reprocessing procedures and the maximum number of cycles, and reflect both in the instructions for use.

5. Verification checklist

• □ The biological evaluation states the contact nature and duration determination
• □ The sterilisation validation report includes validation and routine control records
• □ Shelf-life validation covers the worst-case conditions
• □ Packaging validation conforms to the ISO 11607 series (consensus standard)
• □ Reusable devices have evidence of the maximum reprocessing cycle limit
• □ All of the above evidence is linked clause by clause in the GSPR matrix

Regulatory information verified as of 2026-10-29.

GRZAN supports medical device manufacturers entering and maintaining the EU market under Regulation (EU) 2017/745. Our team structures biological evaluation, sterilisation and shelf-life evidence against MDR Annex I Chapter II and integrates it into the GSPR matrix and notified body submissions. For technical file and conformity support for the EU MDR market, contact info@grzanglobal.com.